Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BM00x
- Development stage
- Preclinical
- Lead developer
- BIMINI Biotech
- Modality
- Small Molecules
01
Overview
BM00x is a preclinical-stage drug candidate within the pipeline of **BIMINI Biotech**. It represents a series of compounds, likely small molecules, designed to modulate the **growth hormone receptor (GHR)** signaling pathway. BIMINI Biotech's research focus is on developing GHR antagonists to treat growth-hormone-dependent diseases, including various forms of **cancer** and **metabolic disorders**. While the specific therapeutic indication for BM00x is currently listed as 'to be determined,' the program is part of the company's broader effort to translate academic research on GHR inhibition into clinical therapies.
02
Targets
WAS (Wiskott-Aldrich syndrome protein)
Beyond the preview
Go deeper on BM00x.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BM00x.